Zymeworks Inc

After a sharp markup and subsequent peak above the fast EMAs, ZYME has pulled back into a support confluence around the 9 EMA, 20 EMA, and 50 SMA. The medium-term bias remains bullish within a broader long-term uptrend, but short-term momentum is negative as price trades below the fast EMAs and the RSI has rolled over. Execution should be deferred, stalking for stabilization at the EMA/SMA zone before initiating a position. Key risks include a breakdown below the 50 SMA and 200 DMA that would shift the medium-term structure.

• ↑Xanadatamab PDUFA on Aug 25, 2026 could yield $250M milestone payment
• ↑Phase 1 ZW191 data show 68% response rate in heavily pre-treated ovarian patients
• ↓Negative earnings yield and net loss of $44.2M in Q1 2026 hinder returns